These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17658374)

  • 1. Dual inhibition of the renin system by aliskiren and valsartan.
    Birkenhäger WH; Staessen JA
    Lancet; 2007 Jul; 370(9583):195-196. PubMed ID: 17658374
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
    Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
    Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
    Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM
    Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of the renin system by aliskiren and valsartan.
    Oparil S; Yarows SA; Patel S; Zhang J; Satlin A
    Lancet; 2007 Sep; 370(9593):1126-7. PubMed ID: 17905160
    [No Abstract]   [Full Text] [Related]  

  • 5. Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.
    Higashikuni Y; Takaoka M; Iwata H; Tanaka K; Hirata Y; Nagai R; Sata M
    Hypertens Res; 2012 Jan; 35(1):62-9. PubMed ID: 21833001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats.
    Wood JM; Schnell CR; Cumin F; Menard J; Webb RL
    J Hypertens; 2005 Feb; 23(2):417-26. PubMed ID: 15662231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.
    Imanishi T; Tsujioka H; Ikejima H; Kuroi A; Takarada S; Kitabata H; Tanimoto T; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
    Hypertension; 2008 Sep; 52(3):563-72. PubMed ID: 18645051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.
    Oparil S; Yarows SA; Patel S; Fang H; Zhang J; Satlin A
    Lancet; 2007 Jul; 370(9583):221-229. PubMed ID: 17658393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.
    Moniwa N; Varagic J; Ahmad S; VonCannon JL; Ferrario CM
    Ther Adv Cardiovasc Dis; 2012 Feb; 6(1):15-29. PubMed ID: 22222314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
    Azizi M; Ménard J; Bissery A; Guyene TT; Bura-Rivière A
    Clin J Am Soc Nephrol; 2007 Sep; 2(5):947-55. PubMed ID: 17702736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan.
    Chrysant SG
    Drugs Today (Barc); 2010 Mar; 46(3):151-62. PubMed ID: 20467589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases.
    Yarows SA
    Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):19-33. PubMed ID: 20030022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper hypertensive patients: a pooled analysis.
    Giles TD; Alessi T; Purkayastha D; Zappe D
    J Clin Hypertens (Greenwich); 2012 May; 14(5):299-306. PubMed ID: 22533656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of renin-angiotensin-aldosterone system blockade on chlorhexidine gluconate-induced sclerosing encapsulated peritonitis in rats.
    Koçak G; Azak A; Astarcı HM; Huddam B; Karaca G; Ceri M; Can M; Sert M; Duranay M
    Ther Apher Dial; 2012 Feb; 16(1):75-80. PubMed ID: 22248199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
    Sepehrdad R; Frishman WH; Stier CT; Sica DA
    Cardiol Rev; 2007; 15(5):242-56. PubMed ID: 17700383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in Syrian cardiomyopathic hamsters.
    Crespo MJ; Cangiano JL; Altieri PI; Escobales N
    J Cardiovasc Pharmacol; 2012 Jun; 59(6):547-52. PubMed ID: 22370958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
    Koid SS; Ziogas J; Campbell DJ
    Hypertension; 2014 Apr; 63(4):768-73. PubMed ID: 24420538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maximum renal responses to renin inhibition in healthy study participants: VTP-27999 versus aliskiren.
    Barkoudah E; van Thiel BS; Fisher ND; Gregg RA; Danser AH; Moukarbel GV; Hollenberg NK
    J Hypertens; 2016 May; 34(5):935-41. PubMed ID: 26882043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice.
    Yamamoto E; Kataoka K; Dong YF; Nakamura T; Fukuda M; Tokutomi Y; Matsuba S; Nako H; Nakagata N; Kaneko T; Ogawa H; Kim-Mitsuyama S
    Hypertension; 2009 Sep; 54(3):633-8. PubMed ID: 19597038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial.
    Udell JA; Morrow DA; Braunwald E; Swedberg K; Bode C; Rifai N; Brunel PC; Prescott MF; Ren F; Hoffman EB; Scirica BM
    Clin Chem; 2013 Jun; 59(6):959-67. PubMed ID: 23509108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.